A new inununometric two-site sandwich assay is introduced, in which a label-scavenging binding partner is added to the sample in addition to the analyte-binding partner.
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The scavenger binding partner binds excess label antibody, 
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ThRMS: human chorionic gonadotropin . immunofluorometric assay #{149} monoclonal antibodies #{149} alkaline phosphatase One-step sandwich immunoassays, i.e., assays in which the analyte and the label antibody are added without an in-between washing step, are gradually replacing the traditional two-step immunoassays,
given the advantages of faster assays and simpler implementation [1] . However, all one-step sandwich immunoassays are subject to the hook effect, i.e., a decreasing signal for analyte concentrations that exceed the binding capacity of the signal and capture antibody
[I]. The hook effect was first observed by Miles et al.
[2] in a two-step immunoassay, but a more pronounced effect can generally be observed in one-step immunoassays, as reported by Nomura et al. [3] . The effect has generally been considered undesirable, because two different analyte concentrations may produce the same (indistinguish-able) result. To overcome this problem, samples are frequently analyzed in two different dilutions, providing a stronger response for the diluted sample if the hook effect has occurred. Hoffman et al. [4] , moreover, developed an alternative "kinetic rate monitoring
IRMA system" to identify the hook effect, in which the sample is analyzed after different incubation times before equilibrium.
Both of these procedures require an additional analysis step, which complicates the assay. Flow cytometry is a technique for analyzing cells or particles according to their size and the amount of fluorescence bound to them. As proposed by Fulwyler [5] , this technique can utilize particles of different sizes with binding partners of different specificity for quantifying multiple analytes in the same sample. In particle-based immunoassays read by flow cytometry, monosized particles pass one at a time through a focused excitation light beam. The light excites the fluorescence marker specifically bound to each particle. By detecting the emitted fluorescence light pulse and converting it to an electric pulse, one can analyze the individual intensities of a large number of particles and classify these into histograms to obtain an accurate distribution and measure of the mean fluorescence signal from each population or type of particle. In flow-cytometric assays, the hook effect can be identified without additional analysis through simultaneous independent determinations of immunofluorescence from particles of different size. To obtain the additional information required to identify the hook effect, two alternative flow-cytometric approaches relying on this principle have been proposed [6, 7] .
In the present study, we evaluated a new variant of flowcytometric multiobservable assays, based on an assay design proposed by Frengen [8] . These assays involve the use of two particle typesone (MPa) being coated with antibodies directed against the analyte, as in a conventional assay, and the other (MPb) being coated with the analyte itself or with its labelbinding part (Fig. 1) . Alternatively, this second type of particle may be coated with an antiidiotypic antibody directed against the binding site of the label antibody. The MPb particles act as a scavenger and will bind excess label antibody not complexed with the analyte; meanwhile, the ordinary MPa particles bind the analyte, as usual. and SA-PE, sereptavidin-R-phycoerythrin.
MATERIALS

Monoclonal antibodies (mAbs).
The mouse mAbs E26 (IgGl) and E27 (IgG2a) [9] are directed against epitopes on the a-and 13-subunits of hCG, respectively. E26 was used as capture antibody and E27 was used as label antibody. These mAbs were kindly provided by Elisabeth Paus of The Central Laboratory at The Norwegian Radium Hospital, Oslo, Norway.
Mouse mAbs F6 (IgG2a), H7 (IgG2a), and a-H7 (IgGi) [10, 11] (InRo Biomedtek AB, Ume, Sweden) were used in the PLAP assay. The F6 and H7 mAbs, having specificity for different PLAP epitopes, were used as capture and label antibody, respectively; a-H7 is an antiidiotypic mAb directed against the antigen-binding site of H7. PLAP and hCG preparations. Alkaline phosphatase from human placenta was purchased from Sigma (cat. no. P1391). Purified PLAP for calibration was obtained according to procedures previously described [12] . Purified hCG with a specific activity of 16 800 lU/mg (standardized against the 1st International Reference Preparation 75/53 7 for immunoassays) was purchased from Calbiochem (La Jolla, CA; cat. no. 869031).
PREPARATIVE PROCEDURES
Antibody biotinylation. mAbs E27 and H7 were labeled with biotin according to the guidelines given by Bayer and Wilchek [13] and with use of reagents and assay protocols as previously described [9, 14] . read by flow cytometry respectively, as described earlier [14] , 150 jig of antibody per 1 mg of particles. About 80% of the antibody added was permanently bound to the particles. Macroporous particles of 7.5-jim diameter were coated similarly with purified hCG (3-subunit (Calbiochem; cat. no. 969126), 30 jig/mg particles. Analytebinding particles coated with either E26 or F6 were the MPa particles; the particles coated with either /3-hCG or a-H7 were the MPb scavenger particles (Fig. 1) .
ALBA PROCEDURE
In the PLAP assay, 10 volumes of 0.9 mg/L biotinylated H7 was incubated with 1 volume of streptavidin-R-phycoerythrin (SA-PE, cat. no. 9023; Becton Dickinson, San Jose, CA) for at least 15 mm before use. The amount of labeling and the concentration of the label antibody in the PLAP assay were chosen to optimize the assay signal-to-noise ratio (results not shown). For the hCG assay, 1.9 mg/L biotinylated E2 7 was incubated with SA-PE (6:1 by vol) for at least 15 mm before use. The amount of labeling and the concentration of the label antibody were the same as in previous optimizations for the hCG assay [9] .
In each of the two series (PLAP and hCG) of assay reagent tubes, 20 jiL of labeled antibody and 50 jiL of IFMA diluent containing intensity monitoring particles (-6000 particles per milliliter) were mixed with 10 j.tL of analyte sample (PLAP or hCG). Analyte and labeled antibody were preincubated for at least 15 mm, allowing equilibrium to be established, before the particles were added.
All particle types were diluted to 310 mgfL in IFMA diluent before addition to the samples. In both assays, 10 jiL each of MPa and MPb particles were added simultaneously.The mixtures in the assays were then incubated for 2 h on a horizontal rotational shaker at room temperature. Thereafter, small volumes from each sample were measured by flow cytometry, without prior washing, at a sample injection rate of 5 jiL/min for 30 s. To maintain constant incubation times, we added particle suspensions to the assay tubes at 2-mm intervals, allowing an analyzing frequency of one sample per 2 mm. For comparison, assays without the MPb particles were also performed for both PLAP and hCG. (Fig. 2) . If analysis at equilibrium is required, Fig.   2 shows that rapid assay results can be obtained at the expense of sensitivity (signal intensity) by using high particle concentra- tions. The binding kinetics for the particles used in the PLAP assay is slightly slower than expected from the observations of Frengen et al. [9] in a similar experiment with hCG as the analyte. This may imply a slightly lower affinity of the antibodies used in the PLAP assay than the antibodies used in the hCG assay.
FLOW-CYTOMETRIC MEASUREMENTS
The particle concentration of 310 mg/L for both particle types (MPa and MPb) was measured at 2 h, conditions chosen for the present PLAP ALBA to provide a rapid assay with measurement close to equilibrium. Fig. 3 (left) shows the calibration curves for the specific binding particles MPa and the scavenger particles The MPa particles, coated with an antibody against PLAP, gave the expected increase in response to PLAP concentrations of 5-1000 jig/L, but at higher concentrations the hook effect caused a rapid decrease in the MPa response. The MPb particles, which were coated with the antiidiotypic antibody with affinity for the label antibody, gave the expected high response at low PLAP concentrations (where the amount of excesslabel antibody was high), but at PLAP concentrations >10 jig/L the limited amount of uncomplexed labeled antibody causedthe MPb responseto decrease. As Fig. 3 (left, A) Precision profiles (CV) for the calibration curves for MPa and MPb (Fig. 3, left (ALBA), developed in our laboratory, utilizes two distinguishable particle types: one (MPa) that binds the analyte, and one (MPb) that binds excess label antibody. The effect of the latter, scavenger particle (MPb) resembles a washing step by removing uncomplexed label antibody from the solution and thus reduces NSB on MPa. More importantly, we measure the amount of excess label antibody by using the calibration curve for the MPb particles in addition to the ordinary calibration curve for the MPa particles. The MPb curve will show maximum binding for analyte-free samples and a systematically decreasing response as the analyte concentration increases. Hence, plotted together, the resulting set of calibration curves for MPa and MPb provides an unambiguous determination of analyte concentration over an extended working range and eliminates the problems related to the hook effect.
The concentrations of MPa and MPb used in the PLAP assay (Fig. 3, left) were chosen to give a sensitive and rapid assay analyzed close to equilibrium. The lower end of the working range of this assay (<5 jig/L) is comparable with that of other PLAP assays [17] . However, combining the calibration curves for both types of particles provides an unambiguous determination of analyte concentration over a working range of >5 log10 orders (Fig. 3) . Because the assay presented has not been systematically optimized with respect to detection limit, further improvements of assay sensitivity can probably be achieved. For instance, use of a lower concentration of MPa will give an
The standard deviation (oD) 
For each pair of D,, and D,, measurements, the weighting parameter a is determined from statistical theory to minimize the variance of Dy,, which will be equal to or less than the lower of the variances of D and Db [7] . With an upper CV limit of 10%, the ALBA provides unambiguous determinations for PLAP dilutions over a working range covering >5 log10 orders (<5 jig/L to >0.8 g/L).
As an alternative to the PLAP assay, we present another approach to verify the ALBA analysis, this time coating the scavenger particles MPb with the fragment of the analyte that binds the labeled antibody, as illustrated in Fig. 1. Fig. 3 (right, A) shows an hCG assay in which the MPa particles were coated with an antibody against the ta-subunit of hCG and the scavenger MPb particles were coated with the hCG (3-subunit. Both particle types were used at 310 mg/L, and the assay tubes were incubated for 2 h before analysis, allowing the binding reaction of the MPa particles to approach equilibrium.
Compared with the MPb particles in the PLAP assay (Fig. 2B) , the MPb particles in the hCG assay showed much slower binding kinetics, reaching equilibrium only after >24 h of incubation (results not shown). After 2 h of incubation, the MPb particles had bound (4) increased signal-to-noise ratio (Fig. 2) Noticeable reverse reaction of the analyte-bound label will not be induced during the incubation periods used, as evidenced by the unchanged specific binding to the MPa particle (Fig. 3, both  A panels) .
In the ALBA of hCG, the scavenger MPb particles are coated with the part of the analyte that binds the label antibody (/3-hCG). The 13-hCG subunit, rather than the entire analyte, was chosen to prevent possible problems caused by leakage of analyte from the MPb particles. If intact analyte were used, and some of it were lost from the MPb particles, this would add to the amount of analyte in the sample and result in falsely high MPa responses for low analyte concentrations. The binding characteristics of the MPb particles would, however, be practically unaffected by this leakage, because only very small fractions would be assumed to loosen. These alternative assay designs show the versatility of the ALBA, indicating that the scavenger MPb particles may be coated with any ligand having affinity for the antigen-binding site of the label antibody. Generally, Fig. 3 shows that the reduction of the NSB signal is limited, typically 4 and 5 channel units (i.e., 15-25%), when the scavenger MPb particles are added in rapid assays. From this we conclude there is still potential for further reducing the NSB in these setups, thus further improving the sensitivity of the ALBA analysis. For both assays, preincubation with MPb particles before adding the MPa particles substantially reduced NSB but also the signal-to-noise ratio, thus preventing the use of this procedure (results not shown). Theoretically, if all excess label antibody is removed, the source of NSB will be eliminated, leaving only the autofluorescence of the particles as a limitation in the assay sensitivity. A nonimmunoreactive fraction of label antibody and traces of uncomplexed SA-PE in the assay tubes are probably the main reasons for the limited efficiency of the scavenger MPb particles in the present PLAP and hCG assays. A more pronounced NSB reduction and thereby improved ALBA results can probably be obtained if purified label antibody or directly labeled antibody is used. The dual-affinity assay of Lindmo et al. [6] and the sequential-binding assay of Frengen et al. /7] are alternative assay designs with qualities similar to the ALBA, both being able to eliminate the hook effect ambiguity and thus increase the assay working range. These assays eliminate the hook effect ambiguity by utilizing two distinguishable particle types coated with antibodies of the same specificity. In both cases, the calibration curves from the two independent particle types show the typical shape of a proportional dose-response sandwich assay curve, but the curves are shifted with respect to each other along the analyte concentration axis. For the dual-affinity assay, this shift was obtained by using antibodies of the same specificity but different affinity on the different particle types. In general, antibodies of identical specificity and different affinity may be hard to come by. For the sequential-binding assay, both particle types were coated with the same antibody, but the particle types were used at different concentrations and added to the sample at different times. This procedure requires at least two processing steps for addition of particles, which complicates the assay design.
In the ALBA setup, all particle types can be added simultaneously, as shown in the hCG and PLAP assays, thus simplifying the implementation of the assay. The ALBA system also provides a more clear-cut identification of the hook effect by the large response differences between high-and low-dose samples in the decreasing MPb calibration curve. Moreover, the ALBA has the potential to remove all excess label antibody and thus minimize the NSB on the MPa particles. The challenge in establishing an ALBA system is to obtain a relevant binding protein for the scavenger particle with the required efficiency. Antiidiotypic antibodies against the labeled antibody used in common immunometric assays may not be easily obtained. Alternatively, by coating the MPb particles with the analyte or the label-binding part of the analyte, as in the hCG assay presented, this procedure should theoretically be applicable to a large number of analytes. The ALBA design should generally be considered for assays where an extended working range is required. The NSB-reducing characteristics of this assay should be further investigated by using high-affinity antibodies and direct labeling to yield rapid, highly sensitive assays.
Eliminating the hook effect ambiguity and thus maintaining only one analysis step improves the overall assay speed and makes the ALBA a valuable alternative to other immunometric assays [4, 6, 7] . The ALBA principle is most readily implemented in flow-cytometric immunoassays, where a new measurement parameter can be included by introducing another particle type, distinguishable from the ones already in use by (e.g.) a difference in size. However, the ALBA principle can also be implemented in conventional immunometric assays using microtiter plates by introducing another solid phase that will capture the unused, excess label. Magnetic beads may be a good candidate for such a scavenging solid phase. By subjecting the excess label to measurement rather than washing it off and thereby losing its information, the advantage of the ALBA will be realized. 
